Clinical Trial Update: The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate-release tablets in HIV-infec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• abacavir/dolutegravir/lamivudine dispersible and immediate-release tablets

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-13